Videos

With the CMSC 2021 annual meeting having wrapped up, the director of the Multiple Sclerosis/MRI Research Group at the University of British Columbia offered his perspective on this year’s conference. [WATCH TIME: 1 minute]

An expert provided context on a subanalysis of the EXPAND study that evaluated the effect of baseline age on the efficacy and safety of siponimod (Mayzent; Novartis) in secondary progressive multiple sclerosis.

The director of the Multiple Sclerosis/MRI Research Group at the University of British Columbia spoke to some of the newer biomarkers and measures being assessed in the clinical management of multiple sclerosis. [WATCH TIME: 3 minutes]

The post-doctoral scholar at the University of Iowa outlined his presentation at CMSC 2021 which focused on the use of elimination diets to improve symptoms of MS. [WATCH TIME: 2 minutes]

The director of the Multiple Sclerosis/MRI Research Group at the University of British Columbia spoke to the portable Standardized MRI Protocol card that is being distributed in an effort to better inform the community to follow the newly published guidelines. [WATCH TIME: 2 minutes]

An expert discusses takeaways about the anti-CD20 monoclonal antibody class of disease-modifying therapies for patients with relapsing multiple sclerosis through the lens of ofatumumab (Kesimpta; Novartis).

Panelists describe the motor and non-motor symptoms of Parkinson’s disease, linking symptoms to OFF episodes, and how to educate patients.

A discussion on how patients are evaluated for OFF episodes, by expert neurologists.

An expert discusses real-world data for ofatumumab (Kesimpta; Novartis), the first self-administered anti-CD20 monoclonal antibody, in patients with relapsing multiple sclerosis.

Following the approval of 3 treatments for the disease, the clinical research director of the UCSF Multiple Sclerosis Center commented on the implications for the clinical development pipeline. [WATCH TIME: 4 minutes]

Neurology News Network for the week ending October 23, 2021. [WATCH TIME: 3 minutes]

Discussing a 6-week, virtual program conducted over Zoom, the founder of First Coast Integrative Medicine, spoke on the use of telehealth and future research efforts for integrative medicine in MS. [WATCH TIME: 3 minutes]

The professor of neurology at the NYU Grossman School of Medicine discussed his findings presented at ECTRIMS 2021, which did not support the hypothesis of a wearing off effect with ocrelizumab (Ocrevus; Genentech). [WATCH TIME: 4 minutes]

Chaired by Devon Conway, MD, the presentations also feature Cleveland Clinic experts Kedar Mahajan, MD, PhD; Marisa McGinley, DO; and Amy Kunchok, MD. [WATCH TIME: 1 hour, 33 minutes]

The duo from MedStar Georgetown University Hospital detailed the need for education on Parkinson disease and movement disorder therapies, and the CME activities they’ve developed with the PMD Alliance to address those needs. [WATCH TIME: 5 minutes]

The founder of First Coast Integrative Medicine spoke on a 6-week virtual program that introduced IM modalities, including guided journaling, nutrition, and yoga. [WATCH TIME: 3 minutes]

The director of the VA Southwest Parkinson’s Disease Research, Education, and Clinical Centers spoke to the importance of utilizing palliative care principles in the regular care of Parkinson disease. [WATCH TIME: 7 minutes]

Ahmed Obeidat, MD, PhD; Jeffrey Cohen, MD; and Erin Longbrake, MD, PhD discuss the evolution of fellowship training for multiple sclerosis specialists.

Discussing this year’s virtual ECTRIMS conference, the Zimmermann Professor of Neurology and Neurological Sciences, and Pediatrics at Stanford University provided his opinion on recent developments in the MS field. [WATCH TIME: 3 minutes]

The professor of neurology at the NYU Grossman School of Medicine provided context on the preliminary data evaluating antibody response in ocrelizumab-treated patients post-vaccine. [WATCH TIME: 5 mintues]

The Zimmermann Professor of Neurology and Neurological Sciences, and Pediatrics at Stanford University discussed the treatment’s potential in the multiple sclerosis space, where there are other competing drugs with similar safety profiles. [WATCH TIME: 4 minutes]

The headache specialist at Jefferson Headache Center discussed the need to revamp the education process for migraine care and how much time residents spend learning about the disease. [WATCH TIME: 2 minutes]

Dr Brian G. Weinshenker envisions the future management of neuromyelitis optica spectrum disorders based on his involvement in research programs and treatment advances occurring in neurology.

Patients with neuromyelitis optica spectrum disorders highlight the types of resources and support that have helped them manage their neurological condition.

Physicians explain expected versus unexpected OFF episodes and the use of symptom diaries in managing Parkinson’s disease.

Jacinta M. Behne, MA, of the Guthy-Jackson Charitable Foundation, reacts to the types of research programs the organization has been involved in, regarding better treatments for patients with neuromyelitis optica spectrum disorders.

Key opinion leaders provide insight on how OFF episodes affect patients’ quality of life.

After showing potential remyelination effects, the director of the Multiple Sclerosis Center at Ochsner Health offered her perspective on the latest data for ATA188 in progressive MS. [WATCH TIME: 4 minutes]

The professor of neurology at the NYU Grossman School of Medicine discussed the trial design of VIOLA, a new prospective study evaluating responses to COVID-19 vaccines in patients with MS on ocrelizumab (Ocrevus; Genentech). [WATCH TIME: 3 minutes]

In light of the RISE-PD study data, the research chair for Parkinson’s Disease and Movement Disorders at University of Cincinnati Health offered insight into IPX-203 in Parkinson disease. [WATCH TIME: 3 minutes]